Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug - KIVIRID

Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug

Authors: Jeanne Lenzer, Shannon Brownlee

Published: 2024-09-26

DOI: 10.1136/bmj.q2010

Source: Full article

Abstract

No abstract found.